The CURB-2 Study is a phase 2, 8-week, randomized placebo controlled trial, studying the efficacy of a combination of extended-release Naltrexone and extended-release Buprenorphine compared to matched placebo injections for the treatment of cocaine use disorder (CUD).
What is the purpose of this study?
The purpose of this study is to see if a combined treatment of injectable extended-release naltrexone (XR-NTX; Vivitrol®) and injectable extended-release Buprenorphine (XR-BUP; Sublocade®) are safe and effective for helping people cut down or stop using cocaine.
You may qualify if you are:
- 18-65 years of age;
- Interested in reducing or stopping cocaine use;
- Be willing to comply with all study procedures and medication instructions.